Flubromazepam Powder
€ 60,00 – € 400,00Price range: € 60,00 through € 400,00
Flubromazepam Powder is described as a crystalline research material containing flubromazepam, a halogenated 1,4-benzodiazepine compound.
The supplied specifications report the chemical name 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one, CAS number 2647-50-9, molecular formula C15H10BrFN2O, and molecular weight approximately 333.16 g/mol.
The source describes white crystalline powder supplied in nominal 1 g portions.
It also claims ingredient purity of at least 98%, independent analytical testing, batch traceability, and controlled manufacturing.
No actual batch-specific Certificate of Analysis, impurity profile, or independent laboratory report was supplied.
The claimed purity, physical appearance, and packaging specifications therefore remain unverified.
Flubromazepam is associated with benzodiazepine-related hazards, including prolonged sedation, impaired coordination, dependence, and respiratory depression, particularly when combined with other central nervous system depressants.
The material is not established as a certified reference standard or approved pharmaceutical product.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Flubromazepam Powder – Research Material Information
Flubromazepam Powder – Product Overview
Flubromazepam Powder is the supplied catalog designation for a crystalline research material described as containing flubromazepam.
The source identifies the compound as a halogenated 1,4-benzodiazepine and reports a nominal product portion of 1 g.
This is a packaging claim rather than an independently verified net-content measurement.
The source positions the material within laboratory contexts involving benzodiazepine chemical identity, structural characterization, and analytical documentation.
No actual batch-specific Certificate of Analysis, independent laboratory report, or finished-product inspection record was supplied.
The material is not established as a certified reference standard or approved pharmaceutical product.
Chemical Identity & Classification
Flubromazepam is described as a halogenated 1,4-benzodiazepine with bromine and fluorine substitutions.
The source provides the following specifications:
- Reported chemical name: Flubromazepam
- Supplied systematic name: 7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
- Reported CAS number: 2647-50-9
- Reported molecular formula: C15H10BrFN2O
- Reported molecular weight: 333.16 g/mol
- Reported form: Crystalline powder
- Nominal portion: 1 g
- Intended designation: Research Use Only
The supplied formula and molecular weight are consistent within normal rounding.
However, numerical consistency alone does not establish the identity or purity of the supplied material.
The CAS number, actual chemical form, and structural assignment should be verified against authoritative records and batch-specific documentation.
Public chemical-reference information can be reviewed through PubChem, ensuring that any selected record corresponds to the intended compound.
Chemical & Physical Characteristics
The source describes the material as a white crystalline powder.
No actual product inspection report, particle-size distribution, polymorph characterization, or verified physical specification was supplied.
The source refers to solubility, thermal stability, and quantitative recovery as analytical considerations.
However, no validated product-specific measurements were provided.
The source also does not establish the impurity profile, residual moisture content, or long-term stability of the supplied powder.
Descriptions of appearance or physical form should therefore be treated as source-reported information rather than verified batch characteristics.
Purity & Analytical Verification
The source claims ingredient purity of at least 98% by HPLC.
It also refers to HPLC, mass spectrometry, and NMR spectroscopy for identity confirmation.
No chromatogram, mass spectrum, NMR spectrum, impurity report, or batch-specific Certificate of Analysis was supplied.
The claimed purity therefore remains unverified.
A purity percentage alone does not establish full chemical identity, impurity characterization, or quantitative reference-material suitability.
The source describes laboratory analytical applications, but no validated quantitative reference value or certified reference-material documentation was supplied.
The material should not be described as a certified analytical standard without appropriate supporting records.
Quality Control & Batch Integrity
The source claims third-party laboratory testing, batch traceability, controlled manufacturing, and residual-solvent analysis.
These claims are not supported by supplied batch-specific documentation.
No independent laboratory report, manufacturing record, residual-solvent dataset, or traceability record was provided.
A nominal 1 g package designation does not establish verified net content.
Ingredient purity, identity confirmation, impurity profiling, and package quantity are distinct measurements.
The Research Use Only designation does not independently demonstrate certified quality or validated analytical performance.
Safety, Handling & Laboratory Precautions
Flubromazepam is a pharmacologically active benzodiazepine associated with central nervous system depression.
Potential hazards include prolonged sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.
Combining benzodiazepines with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.
The source does not provide a verified product-specific Safety Data Sheet.
Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.
The powder presentation does not imply suitability for human or animal administration.
Packaging, Labeling & Storage
The source describes nominal 1 g portions supplied in resealable, inert packaging.
No actual packaging specification, container-validation record, or verified net-content measurement was supplied.
The source recommends storage at approximately -20°C in a dry environment protected from light and moisture.
No validated finished-product stability study was provided to establish that temperature as a confirmed storage requirement.
The source does not establish a verified shelf life or packaging-protection performance.
Inventory records should distinguish nominal catalog specifications from verified batch information.
Intended Research Use & Market Positioning
The source places flubromazepam within laboratory contexts involving benzodiazepine chemical identity, analytical characterization, and structural comparison.
No certified reference-material status or validated quantitative performance has been demonstrated.
The supplied Raw Lab Chems catalog references include Flubromazepam Pure, Flubromazepam Powder, and Flubrotizolam FANAX Bars.
These listings may describe different chemical compounds or product presentations.
Their chemical identity, formulation equivalence, ingredient purity, and analytical performance have not been independently established.
Catalog relationships should not be interpreted as evidence of interchangeable formulations or certified analytical status.
Ordering, Availability & Fulfillment
The source claims international shipping, tracking, customs documentation, and compliant transport.
No current inventory information, carrier authorization, shipment documentation, or verified delivery information was supplied.
The source also refers to IATA and DOT compliance.
No applicable dangerous-goods classification, transport assessment, or supporting compliance documentation was provided.
No claim is therefore made that worldwide shipment or customs clearance is universally available or legally authorized.
Flubromazepam may be controlled or otherwise restricted under applicable national and international laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Flubromazepam is a benzodiazepine compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.
Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.
No therapeutic approval, consumer-use authorization, or certified analytical status is implied.
| Quantity (0.5 grams) |
2 ,5 ,10 ,20 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.